Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease
NCT02770625 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8
Last updated 2017-07-12
Summary
The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease.
Conditions
- Gaucher Disease, Type 1
Interventions
- DRUG
-
ISU302
60 U/kg given intravenously
Sponsors & Collaborators
-
ISU Abxis Co., Ltd.
lead INDUSTRY
Principal Investigators
-
Amel El Beshlawy, Prof. · Abou El Reesh Children's Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-09-30
- Primary Completion
- 2013-03-31
- Completion
- 2014-08-31
More Related Trials
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2
-
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
NCT06958939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
NCT05728684 ·Status: UNKNOWN ·Phase: NA
-
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
NCT07287982 ·Status: RECRUITING ·Phase: PHASE2
-
Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
NCT00306033 ·Status: COMPLETED ·Phase: PHASE3
-
JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
NCT06797024 ·Status: RECRUITING ·Phase: NA
-
Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome
NCT00004833 ·Status: TERMINATED ·Phase: NA
-
Eliglustat on Gaucher Disease Type IIIB
NCT03519646 ·Status: COMPLETED ·Phase: NA
-
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
NCT03052751 ·Status: COMPLETED ·Phase: PHASE2
-
The Phase I Study of Recombinant Human Nerve Growth Factor Injection
NCT04232332 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
NCT04752566 ·Status: COMPLETED ·Phase: PHASE3
-
An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy
NCT01830972 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
NCT05716035 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
NCT05681715 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions
NCT07025577 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
NCT07250750 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy
NCT02605525 ·Status: WITHDRAWN ·Phase: PHASE2
-
An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
NCT06645197 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
NCT02473952 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
NCT01555580 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
NCT02736188 ·Status: TERMINATED ·Phase: PHASE3
-
Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis
NCT03007004 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT03669588 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
NCT02703051 ·Status: COMPLETED ·Phase: PHASE1